For the patient living with a rare autoimmune condition, or the healthy adult curious whether their saliva sample could move a drug program forward, the path into clinical research has historically run through a clinic coordinator, a fax machine, and a lot of waiting. Joined Bio, a Lexington, Massachusetts company that came out of stealth in October 2025, is trying to redraw that path as a consumer marketplace, where participants share electronic medical record data, ship biosamples from home, and earn up to $250 per study they qualify for [Joined Bio, October 2025].
The patient population the company is courting is deliberately broad: people managing chronic conditions, people with rare diseases, and healthy controls, all of whom can sign up for free and be matched to studies based on their health profile [Joined Bio]. Today, the standard of care for clinical research recruitment looks very different. Sponsors and contract research organizations rely on site-based recruitment through hospitals and academic medical centers, supplemented by registries like ResearchMatch and ClinicalTrials.gov listings. Biospecimen procurement, separately, runs through specialty biobanks and brokers who source banked or prospectively collected samples against detailed protocols. The two workflows rarely meet in one place, and patients themselves almost never see the downstream value of the data and tissue they contribute, a gap Joined Bio has made part of its public pitch [Joined Bio].
The bet
Joined Bio is building a two-sided marketplace. On one side sit participants, who connect their EMR data, complete surveys, and consent to provide biospecimens or join interventional trials. On the other sit researchers at sponsors, biotechs, and academic groups who need matched cohorts and physical samples. The company describes three core capabilities: secure integration of comprehensive EMR data, intelligent participation matching, and nationwide in-home collection [Joined Bio, October 2025]. The in-home piece matters. If samples can be drawn or self-collected at a participant's kitchen table rather than at a research site, the addressable participant pool expands well beyond people who live near an academic medical center, which has long been a structural barrier to trial diversity.
The company has moved quickly on the supply side. In its first year it acquired BioSample Connect, a biospecimen procurement business that works with clinics, hospitals, and sample suppliers [Joined Bio]. In November 2025 it acquired DNAsimple, a participant-facing genetics sample company with an existing donor base [Joined Bio, November 2025; Crunchbase]. Together those deals give Joined Bio both a researcher-facing sales motion and a participant community already accustomed to mailing in saliva kits.
Why it could be big
The tailwinds here are real. Sponsors have spent the past five years under pressure from the FDA and EMA to enroll more representative trial populations, and the FDA's 2022 Diversity Action Plan guidance made cohort composition a regulatory question rather than a goodwill exercise. Decentralized trial designs, accelerated during the pandemic, normalized the idea that consent, data capture, and even sample collection can happen outside a clinic. A platform that can deliver pre-consented, EMR-verified participants matched to a specific protocol, plus the logistics to collect a sample at home, is selling into a procurement problem that sponsors already have budget lines for.
The participant-economics angle is also interesting as a trust play. Joined Bio has explicitly positioned itself against the data-handling failures that surfaced at 23andMe, arguing that aligned incentives and patient control over data sharing differentiate its model [Joined Bio]. Whether that framing converts skeptical consumers is an empirical question, but it is a coherent answer to a real question patients are now asking.
The team and traction
Public LinkedIn profiles place Bill Arteca and Jill Mullan at Joined Bio [LinkedIn]. The company is headquartered in Lexington, Massachusetts and launched its platform publicly in October 2025 [Joined Bio, October 2025]. Two acquisitions inside roughly twelve months, BioSample Connect and DNAsimple, give the company an operating footprint that is unusual for a seed-stage healthtech, and suggest the team is willing to buy capability rather than build every layer from scratch [Joined Bio; Joined Bio, November 2025].
| Milestone | Date |
|---|---|
| Company founded | 2024 |
| BioSample Connect acquisition | 2025 |
| Platform public launch | October 2025 |
| DNAsimple acquisition | November 2025 |
The honest counterfactual
What bears will say is that patient-powered research marketplaces are a category with a long graveyard, and that the binding constraint has rarely been participant willingness. It has been sponsor procurement cycles, protocol-specific inclusion criteria that disqualify most volunteers, and the operational difficulty of turning a self-reported EMR connection into a regulator-grade dataset. PatientsLikeMe, Iodine, and a generation of registry plays found that aggregating patients is easier than monetizing them. What bulls answer, drawing on Joined Bio's own positioning, is that the company is not selling community, it is selling matched biospecimens and EMR-linked cohorts to researchers who already buy both categories today, and that the BioSample Connect acquisition gives it a running revenue motion into life-science buyers from day one rather than a years-long enterprise build [Joined Bio]. Execution on sample chain-of-custody, IRB coverage across states, and the quality of EMR integrations will decide which side is right.
What to watch
The next twelve months will tell. Specific things worth tracking: whether Joined Bio discloses sponsor customers or named pharma partnerships, whether the in-home collection network reaches the geographic coverage the company has claimed, and whether participant retention on the DNAsimple base survives the rebrand. A priced funding round, which has not been publicly reported, would also clarify how the market is valuing the combined entity. For a company barely a year old that has already absorbed two businesses and put a participant-facing product in market, the more interesting question is not whether Joined Bio is moving fast. It is whether the regulatory and scientific rigor can keep pace with the commercial momentum.
Pulse Raman covers biotech, digital health, and clinical AI for Startuply.